COSMETIC SOURCING GUIDE

From peptide raw material to finished cosmetic: EU PIF and U.S. MoCRA files

Hytanbio Tech Editorial · Updated October 31, 2026

Ingredient records support a cosmetic launch, but the finished product needs its own market-specific file. Map the handover from supplier documents to EU and U.S. responsibilities before committing artwork or stock.

A peptide ingredient COA can support a finished cosmetic’s technical file. It cannot stand in for the finished product’s safety assessment, market notification or the responsible party’s obligations. The documents describe different objects and different decisions.

For a China-manufactured cosmetic project intended for overseas markets, map the finished product, destination and responsible parties first. Then request supplier records against the missing parts of that map. This avoids buying a large document package that still leaves the launch file incomplete.

Separate the raw-material record from the market file

The raw-material file identifies what was supplied and the relevant evidence for it. The finished-product file addresses the actual formulation, presentation, intended use and market responsibilities. A supplier may contribute information to both, but the connection must be documented.

Use this as a handover checklist, not a fixed list of mandatory documents for every situation. The assessor or responsible party should identify what is needed for the actual product and applicable framework.

EU cosmetics: connect the PIF, CPSR and notification

The EU framework is established by Regulation (EC) No 1223/2009. Articles 10, 11 and 13 address the safety assessment, Product Information File (PIF) and notification respectively. The Cosmetic Product Safety Report (CPSR) records the safety assessment. The European Commission’s legislation overview explains the responsible-person structure. These are finished-cosmetic responsibilities; an ingredient supplier’s COA does not replace them.

What the supplier needs to help the reviewer connect

Give the reviewer the same material identity that appears in the approved formulation. Connect the supplier code and composition reference to the ingredient record. Where confidential information is required, establish a controlled route to the authorized reviewer instead of substituting a marketing brochure.

Keep the exact formulation version in the handover. A supplier document can be accurate while the launch file is wrong because a later ingredient substitution was never reflected in the assessment.

Record retention and notification are separate tasks

The PIF retention period is ten years after the last batch of the cosmetic product was placed on the market, as described in the Commission’s safety report guidance. Assign who maintains the accessible file and its updates. Separately, the Cosmetic Product Notification Portal (CPNP) is the Commission’s online notification system. A notification should not be described as an approval certificate.

A launch checklist should therefore name the responsible person, file custodian, safety assessment owner and notification owner. Even where one organization performs several roles, record each completed task against the actual finished product.

United States: distinguish facility registration and product listing

The U.S. Food and Drug Administration (FDA) administers the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Its registration and listing page states that covered facilities renew registration every two years and responsible persons provide product-listing updates annually. Exemptions exist and must be evaluated against the actual business and product. FDA also states that it does not issue certificates verifying cosmetic facility-registration compliance.

For context, FDA reported 16,398 active facility registrations and 1,298,361 active product listings as of 30 June 2026 on that same page. These are dated administrative counts. They are not market-size estimates, evidence of product efficacy or proof that any particular supplier or product is approved.

For the purchasing file, ask which entity performs each applicable submission and who maintains the underlying product information. Check that the name and role being discussed match the finished cosmetic’s actual label and supply arrangement. Do not treat a raw-material catalogue entry as a finished-product listing.

Build one handover map with market-specific owners

1. Define the product. Record the final formula revision, intended cosmetic use, pack and label version.
2. Identify the parties. List the manufacturer, brand, importer and applicable responsible person, with each role reviewed for the destination.
3. Connect supplier evidence. Link identity, composition and quality records to the ingredients actually used.
4. Assign market tasks. Name the people handling assessment, file maintenance and applicable notifications or submissions.
5. Control later changes. Route formula, source, packaging and claim changes back to the relevant reviewer before implementation.

This sequence is a proposed project-management method. It does not determine whether a specific product meets every applicable obligation. The useful outcome is a visible owner and evidence reference for each decision.

Keep research-use materials in a separate decision path

A “For research use only” designation is not a route to market a finished cosmetic or a claim of permission for human use. The intended use and product classification must match the actual project. Do not transfer research-use catalogue language into consumer packaging as a substitute for reviewing the product.

What to include in an export project brief

Send the destination market, finished product format, intended claims, formulation status and the parties already appointed. State which supplier records the assessor needs and whether confidentiality arrangements are required. Ask for unresolved information by field, rather than requesting a generic “EU/FDA certificate.”

Our quality documentation page is a starting point for supplier-side information. For a private-label project, use OEM and ODM project support and define responsibility through a quality agreement. Market access decisions should remain with the qualified parties appointed for the actual finished cosmetic and destination.

Common questions